



November 04, 2025

To
The Listing Department,
National Stock Exchange of India Limited
NSE Symbol: **VIJAYA**

To
The Corporate Relations Department,
BSE Limited
BSE Scrip Code: **543350**

Dear Sir/Madam,

Subject: Outcome of the Board Meeting held on Tuesday, November 04, 2025

Ref: Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") as amended from time to time.

We hereby inform you that, the Board of Directors at their meeting held today i.e., on **Tuesday, November 04, 2025**, has inter-alia considered and noted/approved the following matters: -

1. The Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2025. In terms of the above, we enclose herewith the following:
 - a. Unaudited Standalone and Consolidated Financial Results of the Company for the second quarter and half year ended September 30, 2025; and
 - b. Limited review Reports on the Standalone & Consolidated Financial Results for the second quarter and half year ended September 30, 2025.
2. The receipt of the certified true copy of the order dated 13th October 2025 passed by Hon'ble National Company Law Tribunal, Hyderabad Bench, Hyderabad ("NCLT") sanctioning the scheme of Amalgamation ("Scheme") of Medinova Diagnostic Services Limited ("Transferor Company") with and into Vijaya Diagnostic Centre Limited ("Transferee Company") and its shareholders and creditors.
3. **Effective Date:** - The effective date of the Scheme is **Tuesday, 04th November 2025**, being the date on which the certified true copy of the order passed by NCLT sanctioning the Scheme is filed by both the Transferor and Transferee companies with the Registrar of Companies, Hyderabad ("ROC").



Pursuant to the effectiveness of the Scheme on today i.e., Tuesday, 04th November 2025, Medinova Diagnostic Services Limited shall stand automatically dissolved without winding-up and the offices of Directors, Key Managerial Personnel and Statutory Auditors of Medinova Diagnostic Services Limited will stand vacated with effect from 04th November 2025.

4. **Appointed Date:** - The appointed date as per the Scheme is 01st April 2024.
5. **Share Exchange Ratio:** - The share exchange ratio as per the Scheme is as follows:

“For every 22 (Twenty-Two) equity shares of face value of INR 10 (INR Ten only) each fully paid held in the Transferor Company as on the Record Date, the equity shareholders of the Transferor Company shall be issued 1 (One) equity share of face value of INR 1 (INR One only) each fully paid in the Transferee Company.”

6. **Record Date:** - In consultation with the Transferor Company the record date for determining the shareholders of the Transferor Company to whom the shares in Transferee Company would be issued under the Scheme is **Tuesday, 25th November 2025.**

7. **Amendment to Memorandum of Association:**

Pursuant to the effectiveness of the Scheme, the Authorised Share Capital of the Company stands increased to INR 230,500,000 (INR Twenty-Three Crore and Five Lakhs only) divided into 230,500,000 (Twenty-Three Crore and Five Lakhs) Equity Shares of face value of INR 1 (INR One) each. Subsequent to the reclassification and enhancement of the authorised share capital of the Transferee Company the authorised share capital clause of the Memorandum (Clause V) of the Transferee Company shall stand modified and read as follows:

“The Authorised Share Capital of the Company is INR 230,500,000 (Indian Rupees Twenty Three Crore and Five Lakhs only) divided into 230,500,000 (Twenty Three Crore and Five Lakhs) Equity Shares of face value INR 1 (Indian Rupees One only) amounting to INR 230,500,000 (Indian Rupees Twenty Three Crore and Five Lakhs only) with a power to increase or reduce the capital of the Company in accordance with the provisions of the Companies Act, 2013 and to classify or reclassify the Share Capital.”

8. **Cancellation of Share/Investment in Medinova Diagnostic Services Limited (Transferor Company):**



Pursuant to the effectiveness of the Scheme, all the Equity shares, held by the Transferee Company and its nominees, if any, in the Transferor Company, shall be cancelled and extinguished.

Accordingly, the Board of Directors of the Company took note on record the cancellation of investment of 62,02,220 equity shares of face value of INR 10/- each (Indian Rupees Ten only) (constituting i.e. 62.14% stake) held by the Transferee Company in accordance with Scheme of Amalgamation.

9. Noting of “Medinova Millennium MRI Services LLP” as the Wholly owned Subsidiary of the Company:

Pursuant to the effectiveness of the Scheme, all the Assets and Liabilities of Transferor Company shall become Assets and Liabilities of the Transferee Company.

Accordingly, the Wholly Owned Subsidiary of Transferor Company i.e., “**Medinova Millennium MRI Services LLP**” shall become the Wholly Owned Subsidiary of the Transferee Company from the effective date i.e. November 04, 2025.

Details required to be disclosed under the SEBI Listing Regulations read with Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 have been provided in **Annexure – I** to this letter.

The Board Meeting commenced at 01:00 P.M. and concluded at 02:15 P.M. (IST).

Kindly take the same on record.

Thanking You.

Yours Faithfully
For **Vijaya Diagnostic Centre Limited**

Hansraj Singh
Company Secretary & Compliance Officer
M. No. F11438

Encl.: As above



Annexure - I

Details as per Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024

S. No.	Particulars	Details
a.	Name of the target entity, details in brief such as size, turnover etc.	Medinova Millennium MRI Services LLP ("MRI LLP") For other details about the entity please refer point (j) below
b.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The proposed transaction is pursuant to the order dated 13 th October 2025 passed by Hon'ble National Company Law Tribunal, Hyderabad Bench, Hyderabad ("NCLT") sanctioning the scheme of Amalgamation ("Scheme") of Medinova Diagnostic Services Limited ("Transferor Company") with and into Vijaya Diagnostic Centre Limited ("Transferee Company") and its shareholders and creditors. MRI LLP is the Wholly Owned Subsidiary of the Transferor Company, and the Transferor Company is the Subsidiary Company of the Transferee Company. The aforesaid change in the status of MRI LLP is within the group.
c.	Industry to which the entity being acquired belongs	MRI LLP belongs to the Healthcare Industry
d.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The aforesaid change is in line with the Scheme of amalgamation and the order passed by the NCLT.
e.	Brief details of any governmental or regulatory approvals required for the acquisition	No governmental or regulatory approvals required for this acquisition
f.	Indicative time-period for completion of the acquisition	Not Applicable



g.	Nature of consideration - whether cash consideration or share swap and details of the same	Not Applicable
h.	Cost of acquisition and/or the price at which the shares are acquired	Not Applicable
i.	Percentage of shareholding / control acquired and / or number of shares acquired	100%
j.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years' turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>MRI LLP is the Wholly Owned Subsidiary of the Transferor Company and is into the business of healthcare services with its operations located in Kolkata, West Bengal.</p> <p>Date of Incorporation - 21-11-2014</p> <p>LLPIN - AAC-9556</p> <p>Registered Office address - 1, Sarat Chatterjee Avenue, Ravindrasarobar Stadium Kolkata West Bengal 700029</p> <p>Total Obligatory Contribution - ₹ 5,00,00,000/-</p> <p>Actual Contribution Received - ₹ 2,30,27,000/-</p> <p>Last Three Years Turnover (Approx.) - FY 2024-25 - ₹ 2.36 Crores FY 2023-24 - ₹ 2.49 Crores FY 2022-23 - ₹ 2.27 Crores</p>



**VIJAYA
DIAGNOSTIC
CENTRE**

Vijaya Diagnostic Centre Limited
CIN: L85195TG2002PLC039075

Regd. Office: No. 6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India
Phone: 040-23420422, Website: www.vijayadiagnostic.com, Email: ir@vijayadiagnostic.in

Statement of Unaudited Standalone Financial Results for the quarter and year-to-date ended 30 September 2025

(Rs. in Lakhs except as stated)

Sl. No.	Particulars	Quarter ended			Year-to-date ended		Year ended
		30 September 2025	30 June 2025	30 September 2024	30 September 2025	30 September 2024	31 March 2025
		Unaudited	Unaudited (Refer Note 6)	Unaudited (Refer Note 6)	Unaudited	Unaudited (Refer Note 6)	Audited (Refer Note 6)
1	Income						
	(a) Revenue from operations	18,935.33	17,672.53	17,047.65	36,607.86	31,465.52	63,400.30
	(b) Other income	515.21	723.34	459.82	1,238.55	821.97	1,852.09
	Total income	19,450.54	18,395.87	17,507.47	37,846.41	32,287.49	65,252.39
2	Expenses						
	(a) Cost of materials consumed	2,263.79	2,015.86	2,146.71	4,279.65	3,878.47	7,923.24
	(b) Employee benefits expense	2,994.13	2,942.55	2,580.14	5,936.68	5,101.09	10,383.38
	(c) Finance costs	721.18	691.02	606.83	1,412.20	1,211.90	2,499.24
	(d) Depreciation and amortisation expense	1,939.68	1,836.14	1,540.28	3,775.82	3,062.30	6,466.43
	(e) Other expenses	5,826.49	5,705.46	5,246.30	11,531.95	9,793.58	19,624.71
	Total expenses	13,745.27	13,191.03	12,120.26	26,936.30	23,047.34	46,897.00
3	Profit before tax and exceptional items [1-2]	5,705.27	5,204.84	5,387.21	10,910.11	9,240.15	18,355.39
4	Exceptional items (Refer Note 4)	-	-	-	-	-	102.96
5	Profit before tax [3-4]	5,705.27	5,204.84	5,387.21	10,910.11	9,240.15	18,252.43
6	Tax expense						
	(a) Current tax	1,243.90	1,143.10	1,213.91	2,387.00	2,085.01	3,892.56
	(b) Deferred tax	191.29	187.17	198.72	378.46	277.62	766.90
	Total tax expense	1,435.19	1,330.27	1,412.63	2,765.46	2,362.63	4,659.46
7	Profit for the period/year [5 - 6]	4,270.08	3,874.57	3,974.58	8,144.65	6,877.52	13,592.97
8	Other comprehensive income						
	Items that will not be reclassified to profit or loss						
	(a) Remeasurement of defined benefit liability / (asset)	39.50	(9.58)	(4.57)	29.92	(9.14)	(34.84)
	(b) Income-tax relating to above item	(9.94)	2.41	1.15	(7.53)	2.30	8.77
	Other comprehensive income for the period/year (net of tax)	29.56	(7.17)	(3.42)	22.39	(6.84)	(26.07)
9	Total comprehensive income for the period/year [7 + 8]	4,299.64	3,867.40	3,971.16	8,167.04	6,870.68	13,566.90
10	Paid-up equity share capital (Face value of Re. 1 each) (Refer Note 5)	1,027.25	1,026.88	1,026.22	1,027.25	1,026.22	1,026.37
11	Other equity (Refer Note 6)						76,987.33
12	Earnings per equity share (face value of Re. 1 each fully paid up) (Refer Note 5 and 6)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	- Basic (in Rs.)	4.15	3.76	3.87	7.92	6.70	13.23
	- Diluted (in Rs.)	4.14	3.77	3.86	7.91	6.68	13.20

Notes:

- The above standalone financial results of Vijaya Diagnostic Centre Limited ("the Company") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder, other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
 - The above standalone financial results were reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on 04 November 2025. The statutory auditors have carried out limited review of the above results for the quarter and year-to-date ended 30 September 2025. An unmodified report has been issued by them thereon.
 - The Company has one reportable segment (viz. Diagnostic services) as per the requirements of Ind AS 108 "Operating Segments".
 - During the previous year, the Company had incurred an amount of Rs. 102.96 towards acquisition/restructuring related costs. These expenses had been categorised as exceptional items as these were not incurred in the ordinary course of business of operations of the Company.
 - During the quarter and year-to-date ended 30 September 2025, the Company has issued 37,825 and 88,658 equity shares of face value of Re. 1/- each respectively on exercise of employee stock options.
 - The Board of Directors of the Company, at its meeting held on 26 June 2024, approved a Scheme of Amalgamation ("the Scheme") of its subsidiary, Medinova Diagnostic Services Limited ("Transferor Company"), with the Company with effect from 01 April 2024 ("the Appointed Date"), pursuant to Sections 230 to 232 of the Companies Act 2013 and other applicable provisions, and the rules made thereunder. The Scheme was sanctioned by the Hon'ble National Company Law Tribunal, Hyderabad Bench ("NCLT"), vide order dated 13 October 2025 and the certified copies of the order passed by NCLT has also been duly filed with the Registrar of Companies. Accordingly, the Company has accounted for the amalgamation as specified in the Scheme in accordance with the "pooling of interest" method as laid down in Appendix C- 'Business Combinations of Entities Under Common Control' of Ind AS 103, Business Combinations, notified under Section 133 of the Companies Act read with the Companies (Indian Accounting Standards) Rules, 2015 and all the comparatives presented have been restated to give effect of the amalgamation from the beginning of the previous year.
- In giving effect to the amalgamation:
- All the assets, liabilities, reserves and surplus as appearing in the transferor company have been transferred and vested in the Company.
 - In consideration for the above Scheme, the Company will issue 171,792 shares amounting to INR 1,405 lakhs for 3,779,420 shares held by non controlling shareholders of the transferor company. The shares of the Company to be issued to the non-controlling shareholders of the transferor company, on the record date, have been presented under 'Other Equity' as 'Shares pending issuance'.
 - The difference between value of share capital of transferor company and existing investment in the transferor company plus the Shares pending issuance as mentioned above has been transferred to 'Amalgamation Reserve' under 'Other Equity'.
- The Board of Directors at its meeting held on 12 May 2025, had proposed and recommended dividend of Re. 2/- per equity share of Re. 1 each i.e., 200% for the financial year 2024-25, subject to the approval of the members at the ensuing annual general meeting. The same was approved by the shareholders in the Annual General Meeting of the Company held on 05 September 2025 and was paid on 12 September 2025.
 - The results of the Company are available for investors at www.vijayadiagnostic.com, www.nseindia.com and www.bseindia.com

for and on behalf of the Board of Directors of
Vijaya Diagnostic Centre Limited

SUPRITA
SURA REDDY

Digitally signed by
SUPRITA SURA REDDY
Date: 2025.11.04
13:45:19 +05'30'

S Suprita Reddy
Managing Director & CEO
DIN Number: 00263618

Place: Hyderabad
Date: 04 November 2025

Limited Review Report on unaudited standalone financial results of Vijaya Diagnostic Centre Limited for the quarter ended 30 September 2025 and year to date results for the period from 01 April 2025 to 30 September 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Vijaya Diagnostic Centre Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Vijaya Diagnostic Centre Limited (hereinafter referred to as “the Company”) for the quarter ended 30 September 2025 and year to date results for the period from 01 April 2025 to 30 September 2025 (“the Statement”).
2. This Statement, which is the responsibility of the Company’s management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The Company has accounted for the amalgamation of Medinova Diagnostic Services Limited (“transferor company”) with the Company during the quarter and half year ended 30 September 2025 in accordance with the Scheme of Amalgamation approved by the National Company Law Tribunal (NCLT) vide order dated 13 October 2025. The amalgamation has been accounted for by the Company by restating the financial information in the financial results in respect of the prior periods as if it had occurred from the beginning of the preceding year in the financial statements as per the requirement of Indian Accounting Standard.

The corresponding figures for the year ended 31 March 2025, in so far it pertains to the transferor company, have been audited by another auditor who had expressed an unmodified opinion on 3 May 2025.

Similarly, the corresponding figures for the quarter ended 30 June 2025 and for the quarter and half year ended 30 September 2024, in so far it pertains to the transferor company, have been reviewed by another auditor who had expressed an unmodified conclusion on 26 July 2025 and 29 October 2024, respectively.

Limited Review Report (Continued)

Vijaya Diagnostic Centre Limited

6. The standalone interim financial results include the reviewed financial information of the transferor company, whose financial information reflects total assets (before accounting adjustments) of Rs. 659.14 lakhs as at 30 September 2025 and total revenues (before accounting adjustments) of Rs. 188.60 lakhs and Rs. 396.43 lakhs, total net profit after tax (before accounting adjustments) of Rs. 23.76 lakhs and Rs. 59.39 lakhs, total comprehensive income (before accounting adjustments) of Rs. 23.22 lakhs and Rs. 58.30 lakhs, for the quarter ended 30 September 2025 and for the interim period from 01 April 2025 to 30 September 2025 respectively, and cash inflows (net) (before accounting adjustments) of Rs. 20.19 lakhs for the period from 01 April 2025 to 30 September 2025 as considered in the interim financial results, which has been reviewed by other auditor. The other auditor's report on the financial information of the transferor company has been furnished to us by the Company's management and our conclusion on the interim financial results, in so far as it relates to the amounts and disclosures included in respect of the transferor company, is based solely on the report of the other auditor.

Our conclusion is not modified in respect of this matter.

For **B S R and Co**

Chartered Accountants

Firm's Registration No.:128510W

BALKISHAN

KABRA

Digitally signed by BALKISHAN
KABRA
Date: 2025.11.04 14:06:42 +05'30'

Balkishan Kabra

Partner

Hyderabad

04 November 2025

Membership No.: 221202

UDIN:25221202BMOCIA8824



Vijaya Diagnostic Centre Limited
CIN: L85195TG2002PLC039075

Regd. Office: No. 6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India
Phone: 040-23420422, Website: www.vijayadiagnostic.com, Email: ir@vijayadiagnostic.in

Statement of Unaudited Consolidated Financial Results for the quarter and year-to-date ended 30 September 2025

(Rs. in Lakhs except as stated)

Sl. No.	Particulars	Quarter ended			Year-to-date ended		Year ended
		30 September 2025	30 June 2025	30 September 2024	30 September 2025	30 September 2024	31 March 2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited (Refer Note 7)
1	Income						
	(a) Revenue from operations	20,156.18	18,805.31	18,294.82	38,961.49	33,916.50	68,139.01
	(b) Other income	624.86	704.84	450.99	1,329.70	807.39	1,831.95
	Total income	20,781.04	19,510.15	18,745.81	40,291.19	34,723.89	69,970.96
2	Expenses						
	(a) Cost of materials consumed	2,431.93	2,141.27	2,298.81	4,573.20	4,174.58	8,476.35
	(b) Employee benefits expense	3,225.93	3,160.71	2,783.72	6,386.64	5,519.52	11,215.28
	(c) Finance costs	782.72	748.54	646.84	1,531.26	1,273.35	2,674.43
	(d) Depreciation and amortisation expense	2,226.70	2,089.01	1,683.74	4,315.71	3,347.14	7,059.74
	(e) Other expenses	6,315.63	6,149.96	5,614.00	12,465.59	10,500.41	21,125.79
	Total expenses	14,982.91	14,289.49	13,027.11	29,272.40	24,815.00	50,551.59
3	Profit before tax and exceptional items [1 - 2]	5,798.13	5,220.66	5,718.70	11,018.79	9,908.89	19,419.37
4	Exceptional items (Refer Note 4)	-	-	-	-	-	102.96
5	Profit before tax [3 - 4]	5,798.13	5,220.66	5,718.70	11,018.79	9,908.89	19,316.41
6	Tax expense						
	(a) Current tax	1,263.15	1,159.63	1,282.62	2,422.78	2,243.49	4,117.77
	(b) Deferred tax, net	206.68	202.13	223.61	408.81	302.41	819.29
	Total tax expense	1,469.83	1,361.76	1,506.23	2,831.59	2,545.90	4,937.06
7	Profit for the period/year [5-6]	4,328.30	3,858.90	4,212.47	8,187.20	7,362.99	14,379.35
8	Other comprehensive income						
	Items that will not be reclassified to profit or loss						
	(a) Remeasurement of the defined benefit obligations	39.50	(9.58)	(4.57)	29.92	(9.14)	0.53
	(b) Income-tax relating to above item	(9.94)	2.41	1.15	(7.53)	2.30	(0.14)
	Other comprehensive income for the period/year (net of tax)	29.56	(7.17)	(3.42)	22.39	(6.84)	0.39
9	Total comprehensive income for the period/year [7+8]	4,357.86	3,851.73	4,209.05	8,209.59	7,356.15	14,379.74
10	Paid-up equity share capital (Face value of Re. 1 each) (Refer Note 5)	1,027.25	1,026.88	1,026.22	1,027.25	1,026.22	1,026.37
11	Other equity (Refer Note 7)						78,887.88
12	Earnings per equity share (Face value of Re. 1 each fully paid up) (Refer Note 5 and 7)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	- Basic (in Rs.)	4.21	3.76	4.10	7.96	7.17	13.99
	- Diluted (in Rs.)	4.20	3.75	4.09	7.95	7.15	13.97

Notes:

- The above consolidated financial results of Vijaya Diagnostic Centre Limited ("the Company") and its subsidiaries (the Company and its subsidiaries together referred to as "the Group") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 (the Act) read with the relevant rules thereunder, other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended).
- The above consolidated financial results were reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on 04 November 2025. The statutory auditors have carried out limited review of the above results for the quarter and year-to-date ended 30 September 2025. An unmodified report has been issued by them thereon.
- The Group has one reportable segment (viz. Diagnostic Services) as per the requirements of Ind AS 108 "Operating Segments".
- During the previous year, the Company had incurred an amount of Rs. 102.96 towards acquisition/restructuring related costs. These expenses had been categorised as exceptional items as these were not incurred in the ordinary course of business of operations of the Company.
- During the quarter and year-to-date ended 30 September 2025, the Company has issued 37,825 and 88,658 equity shares of face value of Re. 1/- each respectively on exercise of employee stock options.
- The Board of Directors at its meeting held on 12 May 2025, had proposed and recommended dividend of Re. 2/- per equity share of Re. 1 each i.e., 200% for the financial year 2024-25, subject to the approval of the members at the ensuing annual general meeting. The same was approved by the shareholders in the Annual General Meeting of the Company held on 05 September 2025 and was paid on 12 September 2025.
- The Board of Directors of the Company, at its meeting held on 26 June 2024, approved a Scheme of Amalgamation ("the Scheme") of its subsidiary, Medinova Diagnostic Services Limited ("Transferor Company"), with the Company with effect from 01 April 2024 ("the Appointed Date"), pursuant to Sections 230 to 232 of the Companies Act 2013 and other applicable provisions, and the rules made thereunder. The Scheme was sanctioned by the Hon'ble National Company Law Tribunal, Hyderabad Bench ("NCLT"), vide order dated 13 October 2025 and the certified copies of the order passed by NCLT has also been duly filed with the Registrar of Companies. Accordingly, the Company has accounted for the amalgamation as specified in the Scheme in accordance with the "pooling of interest" method as laid down in Appendix C- "Business Combinations of Entities Under Common Control" of Ind AS 103, Business Combinations, notified under Section 133 of the Companies Act read with the Companies (Indian Accounting Standards) Rules, 2015 and all the comparatives presented have been restated to give effect of the amalgamation from the beginning of the previous year. In giving effect to the amalgamation:
 - All the assets, liabilities, reserves and surplus as appearing in the Transferor Company have been transferred and vested in the Company.
 - In consideration for the above Scheme, the Company will issue 171,792 shares amounting to INR 1,405 lakhs for 3,779,420 shares held by non controlling shareholders of the transferor company. The shares of the Company to be issued to the non-controlling shareholders of the Transferor Company, on the record date, have been presented under 'Other Equity' as 'Shares pending issuance'.
- The results of the Group are available for investors at www.vijayadiagnostic.com, www.nseindia.com and www.bseindia.com.

for and on behalf of the Board of Directors of
Vijaya Diagnostic Centre Limited

SUPRITA
SURA REDDY

Digitally signed by
SUPRITA SURA REDDY
Date: 2025.11.04
13:40:25 +05'30'

S Suprita Reddy
Managing Director & CEO
DIN Number: 00263618

Place: Hyderabad
Date: 04 November 2025

Unaudited Consolidated Balance sheet		(Rs. in Lakhs except as stated)	
Sl. No.	Particulars	As at	As at
		30 September 2025	31 March 2025
		Unaudited	Audited (Refer Note 7)
	ASSETS		
I	Non-current assets		
	(a) Property, plant and equipment	52,626.85	44,686.96
	(b) Capital work-in-progress	4,528.74	7,026.02
	(c) Right-of-use assets	31,711.39	27,684.00
	(d) Goodwill	11,920.49	11,920.49
	(e) Other intangible assets	2,132.04	2,189.11
	(f) Financial assets		
	(i) Investments	4.00	4.00
	(ii) Other financial assets	1,674.08	1,649.33
	(g) Other tax assets, (net)	141.87	119.50
	(h) Other non-current assets	2,287.09	1,361.60
	Total non-current assets	1,07,026.55	96,641.01
II	Current assets		
	(a) Inventories	358.21	493.27
	(b) Financial assets		
	(i) Investments	22,867.54	18,460.13
	(ii) Trade receivables	1,194.79	1,475.87
	(iii) Cash and cash equivalents	2,420.68	1,280.11
	(iv) Bank balances other than (iii) above	507.59	3,607.77
	(v) Other financial assets	3,894.84	4,778.61
	(c) Other current assets	799.94	624.87
	Total current assets	32,043.59	30,720.63
	TOTAL ASSETS (I + II)	1,39,070.14	1,27,361.64
	EQUITY AND LIABILITIES		
I	Equity		
	(a) Equity share capital	1,027.25	1,026.37
	(b) Other equity	85,480.03	78,887.88
	Total equity	86,507.28	79,914.25
II	Liabilities		
	Non-current liabilities		
	(a) Financial liabilities		
	(i) Lease liabilities	34,465.03	29,641.43
	(b) Provisions	1,079.07	986.84
	(c) Deferred tax liabilities, (net)	943.94	527.58
	(d) Other non-current liabilities	42.22	30.14
	Total non-current liabilities	36,530.26	31,185.99
III	Current liabilities		
	(a) Financial liabilities		
	(i) Lease liabilities	2,061.59	2,316.24
	(ii) Trade payables		
	- Total outstanding dues of micro enterprises and small enterprises; and	144.37	109.27
	- Total outstanding dues of creditors other than micro enterprises and small enterprises	3,837.98	3,204.12
	(iii) Other financial liabilities	8,062.21	9,245.46
	(b) Other current liabilities	580.20	442.75
	(c) Provisions	663.49	598.47
	(d) Current tax liabilities (net)	682.76	345.09
	Total current liabilities	16,032.60	16,261.40
	Total liabilities (II + III)	52,562.86	47,447.39
	TOTAL EQUITY AND LIABILITIES (I + II + III)	1,39,070.14	1,27,361.64

for and on behalf of the Board of Directors of
Vijaya Diagnostic Centre Limited

SUPRITA Digitally signed
SURA by SUPRITA SURA
REDDY REDDY
Date: 2025.11.04
13:40:58 +05'30'

S Suprita Reddy
Managing Director & CEO
DIN Number: 00263618

Place: Hyderabad
Date: 04 November 2025

Limited Review Report on unaudited consolidated financial results of Vijaya Diagnostic Centre Limited for the quarter ended 30 September 2025 and year to date results for the period from 01 April 2025 to 30 September 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Vijaya Diagnostic Centre Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Vijaya Diagnostic Centre Limited (hereinafter referred to as “the Parent”), and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”) for the quarter ended 30 September 2025 and year to date results for the period from 01 April 2025 to 30 September 2025 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”).
2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Parent

- a. Vijaya Diagnostic Centre Limited

Subsidiaries

- b. VDC Diagnostic (Karnataka) LLP
- c. Medinova Millenium MRI Services LLP
- d. P H Diagnostic Centre Private Limited
- e. Namrata Diagnostic Centre Private Limited (Struck off on 6 April 2024)
- f. Doctorslab Medical Services Private Limited (Struck off on 6 April 2024)
- g. Medinova Diagnostic Services Limited (Amalgamated with the Parent, effective from 1 April 2024)

Principal Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center,
Western Express Highway, Goregaon (East), Mumbai - 400063

Limited Review Report (Continued)

Vijaya Diagnostic Centre Limited

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 and 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of three subsidiaries included in the Statement, whose interim financial results reflects total assets (before consolidation adjustments) of Rs.8,888.44 lakhs as at 30 September 2025 and total revenues (before consolidation adjustments) of Rs.1,254.48 lakhs and Rs.2,406.65 lakhs, total net profit after tax (before consolidation adjustments) of Rs.90.50 lakhs and Rs.107.49 lakhs and total comprehensive income (before consolidation adjustments) of Rs.90.50 lakhs and Rs.107.49 lakhs, for the quarter ended 30 September 2025 and for the period from 01 April 2025 to 30 September 2025 respectively, and cash inflows (net) (before consolidation adjustments) of Rs.67.84 lakhs for the period from 01 April 2025 to 30 September 2025 as considered in the Statement. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

7. The Statement include the reviewed financial information of Medinova Diagnostic Services Limited ("component") for the quarter and half year ended 30 September 2025, which was amalgamated with the Parent, in accordance with the Scheme of Amalgamation approved by the National Company Law Tribunal (NCLT) vide order dated 13 October 2025 with appointed date 1 April 2024, whose financial information reflects total assets (before accounting adjustments) of Rs. 659.14 lakhs as at 30 September 2025 and total revenues (before accounting adjustments) of Rs. 188.60 lakhs and Rs. 396.43 lakhs, total net profit after tax (before accounting adjustments) of Rs. 23.76 lakhs and Rs. 59.39 lakhs, total comprehensive income (before accounting adjustments) of Rs. 23.22 lakhs and Rs. 58.30 lakhs, for the quarter ended 30 September 2025 and for the interim period from 01 April 2025 to 30 September 2025 respectively, and cash inflows (net) (before accounting adjustments) of Rs. 20.19 lakhs for the period from 01 April 2025 to 30 September 2025 as considered in the Statement, which has been reviewed by other auditor. The other auditor's report on the financial information of the component has been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the component, is based solely on the report of the other auditor.

Our conclusion is not modified in respect of this matter.

For **B S R and Co**

Chartered Accountants

Firm's Registration No.:128510W

BALKISHAN Digitally signed by
KABRA BALKISHAN KABRA
Date: 2025.11.04
14:07:25 +05'30'

Balkishan Kabra

Partner

Hyderabad

04 November 2025

Membership No.: 221202

UDIN:25221202BMOCIB9344